



Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Press Release, Helsinki, 17 July 2026 at 9 AM (EEST)

Nexstim Plc ("**Nexstim**" or "**Company**") announces that Delve Psychiatry, a psychiatric practice based in Las Vegas, Nevada, has updated their existing Nexstim systems to the latest version of NBS 6, further expanding its access to Nexstim's latest neuronavigated TMS capabilities. The transaction reflects Delve Psychiatry's continued commitment to investing in the latest neuronavigated TMS technology and supporting a growing range of treatment options for its patients.

Following the update and system replacement, Delve Psychiatry now operates with Nexstim's latest NBS 6 platform, providing access to SmartFocus® nTMS technology, advanced targeting tools and the latest software features. In addition, the clinic now benefits from the recently FDA-cleared treatment indications for adolescent depression and Obsessive Compulsive Disorder (OCD).

The NBS 6 is Nexstim's latest-generation platform built on the Company's proprietary navigated TMS technology. In the United States, the system is FDA-cleared for the treatment of adult and adolescent Major Depressive Disorder (MDD) as well as Obsessive-Compulsive Disorder (OCD), offering providers access to a broad range of evidence-based personalized neuromodulation treatments.

Delve Psychiatry was founded by John Reitano, MD, a University of Pennsylvania-trained psychiatrist. The clinic, a comprehensive behavioral health practice, has been using Nexstim neuronavigated TMS since 2023.

Dr. John Reitano, founder of Delve Psychiatry, comments:

"We have been very pleased with both the clinical outcomes and the patient experience achieved with Nexstim's technology. Upgrading our systems allows us to provide our patients with access to the latest treatment capabilities while continuing to benefit from the accuracy, precision and consistency of Nexstim's easy-to-use nTMS technology."

Mikko Karvinen, CEO of Nexstim, says:

"We are delighted to see Delve Psychiatry continue investing in Nexstim technology. The decision to upgrade an existing NBS 6 and replace an older-generation system with a new NBS 6 demonstrates the value customers see in our platform. This investment reflects Delve Psychiatry's commitment to providing patients with access to the latest FDA-cleared treatment indications."

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS System 6 is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com.